Abstract 279P
Background
The moderated hypofractionation (MoHF) radiotherapy (RT) protocols offer an alternative treatment (Tx) that solves both the workload issue as well as the duration of Tx for prostate cancer (PC) patients while delivering a more adapted dose to the tumor cells. Therefore, the MoHF protocol has been implemented in our department using the Volumetric Arc Modulated Therapy (VMAT) with Image Guided Radiation Therapy (IGRT) for our PC patients.
Methods
From May 24th 2021 to June 30th 2023, there were totally 23 patients who were applied the MoHF protocols. Initially, we implemented protocol of 60Gy in 20 fractions (60Gy/20fx) for intermediate-risk PC patients. Since December 2022, the protocol of 68Gy in 25 fractions (68Gy/25fx) was implemented for high-risk PC patients based on the new data of PCS5 trial. All patients were treated accordingly to institutional protocol for Tx of PC. A weekly consultation during RT course was also held for each patient to follow up with the possible acute side effects.
Results
The average duration to complete Tx planning was 7 days. For dose constraint achievement, 100% of planning had D2% < 107% of dose prescription while 21/23 plans (91.30%) achieved the criteria of planning target volum (PTV) coverage as well as organs at risk (OARs) protection. 2/23 plans (8.70%) were validated with a minor deviation in either target coverage or OARs constraints. The most common acute toxicity was dysuria which happened on 21/23 cases (91.30%) with grade 1 or 2. This side effect was resolutive in 100% of patients within 1 month after completion of Tx. No grade 3 or higher acute or late toxicity was reported. The cost-effectiveness of the MoHF protocols, was compared to a normo-fractionated protocol in 8 weeks (80Gy/40fx). The cost of RT was reduced by 25% going from more than 7000USD for the 8-weeks protocol to 5800USD for the 68Gy/25fx protocol and to 4900USD for the 60Gy/20fx protocol. The entire treatment costs were further reduced due to lower accommodation and transportation fees in the shorter protocols.
Conclusions
For PC patients indicated with definitive RT, the MoHF is a more convenient and safer alternative with manageable side effects and a reduction of treatment direct and indirect cost.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
73TiP - Global phase III studies evaluating vepdegestrant in estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: VERITAC-2 and VERITAC-3
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
78P - First-in-human phase I study of TT-00434, an orally available FGFR (1-3) inhibitor in patients with advanced solid tumors
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
79P - Accelerated identification of recurrent neoantigens for the development of off-the-shelf cancer vaccines
Presenter: Le Son Tran
Session: Poster Display
Resources:
Abstract
80P - Safety, preliminary efficacy, and pharmacokinetics of HLX26 plus serplulimab in advanced solid tumours: An open-label, dose-escalation phase I study
Presenter: Yanmin Wu
Session: Poster Display
Resources:
Abstract
81P - A first-in-human, multiple dose and dose escalation phase I study to investigate the safety, tolerability and antitumor activity of SmarT cells plus PD-1 blocking antibodies in patients with far advanced/metastatic solid tumors
Presenter: Qin Liu
Session: Poster Display
Resources:
Abstract
82P - NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies
Presenter: Gloria Chan
Session: Poster Display
Resources:
Abstract
83P - The updated report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors
Presenter: Yinan Shen
Session: Poster Display
Resources:
Abstract
84P - T cell receptor repertoire profiles of tumor -infiltrating lymphocytes improves neoantigen prioritization for personalized cancer immunotherapy
Presenter: Tran Nguyen
Session: Poster Display
Resources:
Abstract
85P - Oligometastatic solid tumors: Disease characteristics and role of local therapies
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
86P - Efficacy and safety of HLX07 monotherapy in advanced cutaneous squamous cell carcinoma: An open-label, multicentre phase II study
Presenter: Changxing Li
Session: Poster Display
Resources:
Abstract